Using ‘Big’ For Good In The COVID-19 Challenge

Johnson & Johnson, among world’s largest health care groups, explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.

Global - Local
• Source: Shutterstock

The worldwide chair of medical devices at Johnson & Johnson, Ashley McEvoy, was the first keynote speaker at APACMed’s 2020 virtual annual conference, an event whose content and thrust – as for many others this year – were dictated largely by the ongoing coronavirus pandemic.

McEvoy, also an executive VP and a member of J&J’s executive committee, gave a “big group” take on COVID-19 problem-solving, but also stressed the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By 

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By 

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.